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Abstract
Background: After the implementation of pneumococcal conjugate vaccines (PCVs), the marked shift in Streptococcus
pneumoniae (Pnc) serotype distribution led to a modification in pneumococcal antibiotic susceptibility. In 2011, the
pattern of antibiotic prescription in France for acute otitis media in infants was greatly modified, with decreased use of
third-generation cephalosporins and amoxicillin–clavulanate replaced by amoxicillin alone. To assess antibiotic
strategies, here we measured the antibiotic susceptibility of Pnc and Haemophilus influenzae (Hi) isolated from
nasopharyngeal flora in infants with acute otitis media in the 13-valent PCV (PCV13) era in France.
Methods: From November 2006 to June 2013, 77 pediatricians obtained nasopharyngeal swabs from infants
(6 to 24 months old) with acute otitis media. The swabs were sent for analysis to the national reference centre for
pneumococci in France. Demographics, medical history, and physical examination findings were recorded.
Results: We examined data for 7200 children, 3498 in the pre-PCV13 period (2006–2009) and 3702 in the post-PCV13
period (2010–2013). The Pnc carriage rate decreased from 57.9 % to 54.2 % between the 2 periods, and the proportion
of pneumococcal strains with reduced susceptibility to penicillin or resistant to penicillin decreased from 47.1 % to
39 % (P < 0.0001). The Hi carriage rate increased from 48.2 % to 52.4 %, with the proportion of ß-lactamase–producing
strains decreasing from 17.1 % to 11.9 % and the proportion of ß-lactamase–nonproducing, ampicillin-resistant
strains remaining stable, from 7.7 % to 8.2 %. We did not identify any risk factor associated with
carriage of ß-lactamase–producing Hi strains (such as daycare center attendance, otitis-prone condition or
recent antibiotic use).
Conclusion: In France, the nasopharyngeal carriage rate of reduced-susceptibility pneumococcal strains and ß-
lactamase–producing Hi strains decreased in children with acute otitis media after 2010, the year the PCV13
was introduced. Accordingly, amoxicillin as the first-line drug for acute otitis media requiring antibiotics
remains a valid choice.
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Background
Acute otitis media (AOM) is the most frequent bacterial
infection in childhood and one of the major indications
for antibiotics in many countries [1]. Streptococcus pneu-
moniae (Pnc) and Haemophilus influenzae (Hi) are the
leading bacterial species implicated in AOM, followed by
Moraxella catarrhalis (Mc) and, to a lesser extent, group
A β-hemolytic streptococci [2]. For AOM, Pnc and Hi are
the main targets of antibiotics prescription [3, 4]. Detec-
tion of bacterial species in the middle ear fluid (MEF) by
culture is the “gold standard” for etiologic diagnosis of
AOM [5].
Few medical centers in Europe or the United States con-
tinue to routinely perform tympanocentesis [6, 7]. The de-
crease in centers performing tympanocentesis probably
reflects no new antibiotics introduced for AOM [5]. Tym-
panocentesis or myringotomy (both considered painful)
are performed mainly for special circumstances: antibi-
otics non-response, recurrent cases and chronic OM.
Therefore, the profile of antibiotics resistance among oto-
pathogens isolated from MEF could be biased and we have
no current MEF microbiology data on which to base treat-
ment decisions for the most frequent situations: first-line
AOM seen by pediatricians or general practitioners. Be-
cause the microbiology of AOM is linked to nasopharyn-
geal (NP) flora, many studies have assessed the possibility
of using NP culture, a painless procedure, to predict the
bacterial etiology of AOM [5, 8]. These studies have
shown that if Pnc or Hi is not found in the nasopharynx,
the isolates will not likely be found in the MEF in case of
AOM. However, because the causative bacteria of AOM
are often isolated from NP cultures in addition to other
organisms, the positive predictive value of this type of
sample for the causative agent is poor [9].
For these reasons, NP culture has not been considered
a useful predictor of AOM etiology in clinical practice.
However, if NP cultures are not useful for treatment for
specific patients with AOM, they may be useful on a
population basis for formulating recommendations in
one country or in different regions [5].
In France, 7 valent pneumococcal conjugate vaccine
(PCV7) was introduced for high risk children < 2 years
old in 2002, then for all children < 2 years old in 2006.
PCV7 coverage reached 86 % in 2008. In June 2010, the
French authorities recommended routine vaccination
with PCV13 of infants at 2, 4 and 12 months old to re-
place PCV7. During a one-year transition period, switch-
ing from PCV7 to PCV13 was recommended at any
point in the schedule to complete the immunization
series. The PCV vaccination coverage for children youn-
ger than 2 years after changing from PCV7 to PCV13 is
greater than 92 % [10].
Since the implementation of PCV7 and PCV13, two
major and related changes have occurred: the Pnc serotype
distribution has shifted, which has led to a modification in
pneumococcal antibiotic susceptibility. The changes in anti-
biotic susceptibility could also result from other factors
such as variations in antibiotic consumption (volume and
type of compound used) or rate of children cared for out-
side the home [3, 4, 11]
Since 2000, to follow the changes induced by PCV im-
plementation, our research group has analyzed several
hundred NP samples from children with AOM all over
France each year [12]. The data obtained during the first
years of the study have served as the basis for the guide-
lines published in 2011 for France [3, 13], which recom-
mended amoxicillin, 80–90 mg/kg/d in 2 or 3 daily
intakes, as first-line therapy for AOM in young children.
Indeed, the guidelines stated that amoxicillin was the
most active agent for pneumococci with decreased sus-
ceptibility to penicillin and was active for more than
85 % of nontypable Hi according to microbiologic data
at the time [3]. Since 2011, 2 major changes have oc-
curred: the implementation of 13-valent PCV (PCV13)
and the shift in antibiotic prescription for AOM, with
decreased use of third-generation cephalosporins and
amoxicillin–clavulanate replaced by amoxicillin [14, 15].
A rapid change in resistance of Pnc and Hi to the
commonly used antimicrobials prompts a reevaluation
of the treatment strategies [8]. To assess this question,
we measured NP carriage and antibiotic susceptibility of
these 2 otopathogens in young children with AOM in
the PCV13 era in France.
Methods
From November 2006 to June 2013, 77 French pediatri-
cians throughout France took part in a cross-sectional
study. An NP swab was obtained from children aged 6
to 24 months with a diagnosis of purulent AOM [16].
We excluded children who had received antibiotics
within 7 days before enrolment, had a severe underlying
health disorder, or had been included in the study during
the previous 12 months. Demographic data, medical his-
tory and physical findings were recorded. To monitor
the impact of the introduction of PCV13 on this eco-
logical niche, 2 periods were defined: pre-PCV13 (2006–
2009) and post-PCV13 (2010–2013).
The study was approved by the Saint Germain en Laye
Ethics Committee (CPP île de France XI, 20 rue Arma-
gis, 78105 Saint Germain en Laye Cedex, France), and
written informed consent was obtained from parents or
guardians.
Microbiology investigations
NP specimens were obtained with use of cotton-tipped
wire swabs. The swabs were inserted into the anterior
nares, gently rubbed on the NP wall and immediately
placed in transport medium (Copan Venturi Transystem,
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Brescia, Italy). The samples were transferred within 48 h
to Robert Debré Hospital and to the national reference
center for pneumococci in France.
Pnc culture, identification, serotyping and antibiotic
susceptibility testing were performed as previously de-
scribed [17]. Susceptibility of Pnc isolates to penicillin
G and erythromycin was determined from minimal in-
hibitory concentrations (MICs) by the agar-dilution
method. Isolates were classified as penicillin-susceptible
(MIC ≤ 0.06 μg/ml), penicillin–non-susceptible (MIC ≥
0.12 μg/ml), penicillin–intermediate-resistant (MIC
0.12–2.0 μg/ml), or penicillin-resistant (MIC > 2 μg/ml)
according to the European Committee on Antimicro-
bial Susceptibility Testing (http://www.eucast.org/clini-
cal_breakpoints/).
Isolates of Hi were identified by colony morphology
assay and conventional methods of determination. Hi
isolates underwent capsular serotyping by the slide ag-
glutination method with specific antisera (Phadebact;
Boule Diagnostics, Huddinge, Sweden). The production
of ß-lactamase was assessed by a chromogenic cephalo-
sporin test (Nitrocefin; Cefinase; Biomerieux, Marcy
l’Etoile, France). H. influenzae strains were further classi-
fied as ampicillin susceptible (MIC ≤ 1 mg/L), or resist-
ant (MIC > 1 mg/L). ß-lactamase negative ampicillin
resistance (BLNAR) was determined according to the
CLSI break points [18]. If the 2 μg ampicillin diffusion
test (Becton Dickinson) gave a zone of inhibition <20 mm
and if the cefalotin disk diffusion test gave a zone of in-
hibition <17 mm, strains were considered BLNAR [19].
Statistical analysis
Data were double-entered by using 4D software 6.4 and
analyzed by using Stata SE 13.1 (Stata Corp., College
Station, TX, USA) for univariate analysis and multivari-
ate logistic regression (odds ratios [ORs] and 95 % confi-
dence intervals [95 % CI]). Chi-square test was used to
compare NP carriage of pneumococci and Hi before and
after PCV13 implementation. Factors related to NP car-
riage were identified on univariate analysis (p < 0.20, chi-
square test). Multivariate logistic regression analysis was
performed to identify the main factors associated with
carriage of Pnc, Pnc strains with reduced susceptibility
to penicillin (RSP), Hi carriage, and ß-lactamase–produ-
cing Hi strains. For these models, factors had to be de-
termined by the physician during the visits. When
different factors were highly correlated, such as recent
antibiotic use, history of AOM and otitis-prone children,
we retained the most relevant factor. The following
variables were included in multivariate logistic regres-
sion models: daycare attendance, siblings, recent anti-
biotic treatment (within 3 months before enrolment),
otalgia + fever ≥38.5 °C, conjunctivitis, and bilateral
AOM. All models were adjusted for age. Age was
dichotomized as <1 and ≥ 1 year. The cut-off of 1 year
was chosen because the vaccination schedules differ
before and after this age (reflecting the immunity
maturation); in many studies, the NP carriage is
higher after 1 year; and in one of our studies, young
age (<1 year) predicted penicillin non-susceptible
pneumococci carriage [20].
Results
During the 7 years, we assessed samples for 7200 pa-
tients (3498 in the pre-PCV13 period and 3702 in the
post-PCV13 period). Table 1 shows demographic charac-
teristics and NP carriage of the children enrolled. Me-
dian age was 13 months (Q1–Q3 9–17 months) and
more than 99 % were PCV-vaccinated, including 3399
(47.2 %) with PCV13. Among the children, 44.8 %
attended a daycare center and 45.1 % had received anti-
biotics within 3 months before inclusion.
The Pnc carriage rate decreased from 57.9 % to 54.2 %
between the pre- and post-PCV13 period, and the pro-
portion of Pnc strains with reduced susceptibility to
penicillin or resistant to penicillin decreased from
47.1 % to 39 % (P < 0.0001) (Table 2 and Fig. 1). In the
pre-PCV13 period, pneumococcal penicillin–non-sus-
ceptible strains were represented by serotypes 19A, 15A,
35B and 19 F. Among the Pnc carriers, between the two
periods, the proportion of PCV7 serotype and 6 add-
itional PCV13 serotypes decreased from 9.5 % to 3.2 %
(P < 0.001) and from 32.0 % to 11.1 % (P < 0.001), re-
spectively. Serotype 19A, the most frequently serotype
identified during the whole study, decreased from 22.6 %
to 8.4 % between the 2 periods. By contrast, non-PCV13
serotypes increased from 58.5 % to 85.7 % (P < 0.001).
The most frequently carried non-PCV13 serotypes in
post PCV13 period were serotype 15B/C (12.2 %), 15A
(9.3 %), 11A (9.1 %), 35B (7.5 %), 23A (5.9 %), and 6C
(5.0 %), 33 other serotypes accounted for 34.9 %. In this
period, pneumococcal penicillin–non-susceptible strains
were predominantly represented by serotypes 11A, 15A,
15B/C, 19A and 35B. Non-typeable Pnc remained stable
(2.1 % to 1.8 %) between the 2 periods.
The Hi carriage rate increased from 48.2 % to 52.4 %
between the pre- and post-PCV13 period. During the
whole study, 18/3624 (0.5 %) Hi isolates were serotype b.
The proportion of ß-lactamase–producing Hi strains de-
creased from 17.1 % (n = 289) to 11.9 % (n = 230) and
that of ß-lactamase–nonproducing, ampicillin-resistant
(BLNAR) strains remained stable, < 10 %, with 7.7 %
and 8.2 % in the pre- and post-PCV13 periods (Table 2).
On multivariate logistic regression analysis (Table 3),
the main factors associated with RSP-Pnc carriage were
daycare center attendance (adjusted OR [aOR] = 1.55,
95 % CI [1.36;1.77]), age < 1 year old (aOR = 1.19, 95 %
CI [1.04;1.35]), and antibiotic use within 3 months
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(aOR = 1.78, 95 % CI [1.56;2.03]. In contrast, de-
creased RSP-Pnc carriage was associated with pres-
ence of siblings and post-PCV13 period (aOR = 0.75,
95 % CI [0.65;0.85]) and (aOR = 0.71, 95 % CI [0.62;0.81]).
Factors associated with Hi carriage were conjunctivitis
(aOR = 4.10, 95 % CI [3.54;4.76]), bilateral AOM (aOR =
1.33, 95 % CI [1.17;1.51]), daycare center attendance
(aOR = 1.93, 95 % CI [1.70;2.19]), age < 1 year old (aOR =
1.49, 95 % CI [1.31;1.69]), presence of siblings aOR = 1.82,
95 % CI [1.60;2.07]), and post-PCV13 period (aOR = 1.23,
95 % CI [1.05;1.44]). Post-PCV13 period was the only fac-
tor retained in the ß-lactamase–producing Hi carriage
model and was associated with decreased carriage
(aOR = 0.65, 95 % CI [0.54;0.79]).
Discussion
The levels of resistance to antibiotic for S. pneumoniae
and H. influenzae are the cornerstones of the rationale
for antimicrobial recommendations for AOM [5, 8]. In
2011, guidelines in France designated amoxicillin as the
first-line drug for AOM requiring antibiotics, with
amoxicillin-clavulanate and cefpodoxime proxetil limited
to rare and specific situations [3]. These guidelines were
based on a decreased proportion of ß-lactamase–produ-
cing Hi strains in France [13]. Complying with these
2011 recommendations, in 2012, the most frequently
(66 %) prescribed antibiotic for AOM in France was
amoxicillin, as was recently shown [14, 15]. Conversely,
prescriptions of broad-spectrum antibiotics such as
Table 1 Characteristics of children with acute otitis media before/after 13-valent pneumococcal conjugate vaccine implementation
in France
Child characteristics Before PCV13 After PCV13 p-value
n = 3,498 (%) n = 3,702 (%)
Male sex 1,848 (52.8) 1,982 (53.5) 0.5
Age (months), mean ± SD 13.5 ± 5.0 13.7 ± 5.0 0.05
Median (Q1-Q3) 12.7 (9.4-17.2) 13.0 (9.5-17.5)
Type of care <0.0001
Daycare center 1437 (41.1) 1784 (48.2)
Childminder 1099 (31.4) 1148 (31.0)
Home 959 (27.4) 770 (20.8)
Antibiotics 3 months before enrolment 1652 (47.3) 1591 (43.0) <0.0001
Only 1 antibiotic 1035 (62.7) 1051 (66.1) 0.04
At least 2 antibiotics 617 (37.4) 539 (33.9)
Cephalosporin 809 (49.1) 393 (24.8)
Amoxicillin-clavulanate 670 (40.7) 561 (35.4) <0.0001
Amoxicillin 116 (7.0) 598 (37.7)
Others antibiotic 52 (3.2) 34 (2.1)
Last antibiotic in
the previous month 607 (36.7) 601 (37.8)
1 to 2 months 681 (41.2) 666 (41.9) 0.50
2 to 3 months 364 (22.0) 324 (20.4)
Sibling 1975 (56.5) 2071 (55.9) 0.65
Conjunctivitis 886 (25.3) 1062 (28.7) 0.001
Otalgia 2595 (74.3) 2686 (72.6) 0.1
Fever (≥38.5 °C) 2061 (59.4) 2052 (55.9) 0.003
Otalgia + fever ≥38.5 °C 1564 (44.7) 1543 (41.7) 0.009
Bilaterala 492/900 (54.7) 1858 (50.2) 0.02
History of AOMb 1005/1793 (56.1) 2047 (55.3) 0.6
Otitis-prone childrenb 349/1793 (19.5) 651 (17.6) 0.09
Pnc carriage 2026 (57.9) 2007 (54.2) 0.002
Hi carriage 1686 (48.2) 1938 (52.4) <0.0001
adata not available in 2006/2008, bdata not available in 2006/2007
AOM: Acute Otitis Media; PCV13: 13-valent pneumococcal conjugate vaccine; Q1-Q3, quartiles 1 to 3; Pnc: pneumococcus; Hi: H. influenzae
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amoxicillin-clavulanate and cefpodoxime proxetil sharply
decreased [14, 15].
Since 2011 (Fig. 1), the NP carriage of RSP-Pnc de-
creased 18 % in the post-PCV13 period. Moreover, this
reduction was associated with a decrease (−20 %) in the
carriage of ß-lactamase–producing Hi strains. Accord-
ingly, amoxicillin as the first-line drug for AOM requir-
ing antibiotics remains an adapted recommendation in
France. In addition, we did not identify any risk factor
associated with carriage of ß-lactamase–producing Hi
strains (such as daycare center attendance, otitis-prone
condition or recent antibiotic use). Taking into account
the low proportion of ß-lactamase–producing Hi strains
and the lack of risk factors associated with their carriage,
the prescription of amoxicillin-clavulanate as the first-
line drug for AOM in this situation seems to have no
benefit or justification.
The decrease in antibiotic resistance to S. pneumoniae
was expected [21]. As in other studies, the reduction is
linked to the 66 % decrease in the 6 additional PCV13
serotypes in our study [21, 22]. Despite a dramatically
decrease of vaccine serotypes, 19A known in France to
harbor a high proportion of RSP remained frequently
isolated in post PCV13 period (8.4 %) [23]. Several non-
vaccine serotypes such as 15B/C (12.2 %), 15A (9.3 %),
11A (9.1 %), 35B (7.5 %), 23A (5.9 %), and 6C (5.0 %)
seem to emerge in the post PCV13 period.
In contrast, the decrease in ß-lactamase–producing Hi
strains was not expected. Two explanations could be
raised. The first is the reduced antibiotic use for children
in France. Since 2001, following a national campaign
Table 2 Nasopharyngeal carriage and resistance of Pnc and Hi
in children with AOM before/after PCV13 implementation
Carriage Before PCV13 After PCV13 p-
valuen = 3,498 (%) n = 3,702 (%)
Pnc 2026 (57.9) 2007 (54.2)
Penicillin susceptible 1069 (52.9) 1223 (61.0) <0.001
Penicillin intermediate-resistant 950 (47.0) 772 (38.5)
Penicillin resistant 3 (0.1) 10 (0.5)
Erythromycin susceptible 1119 (55.3) 1351 (67.4) <0.001
Erythromycin intermediate 109 (5.4) 42 (2.1)
Erythromycin resistant 794 (39.3) 613 (30.6)
PCV7 vaccine types 193(9.5) 64 (3.2) <0.001
Additional PCV13 vaccine types 648 (32.0) 223 (11.1)
Non-vaccine types 1185 (58.5) 1720 (85.7)
Hi 1686 (48.2) 1938 (52.4)
ß-lactamase–producing strains 289 (17.1) 230 (11.9) <0.001
BLNAR+ 130 (7.7) 159 (8.2) 0.74
ß-lactamase + BLNAR- 264 (15.7) 209 (10.8)
ß-lactamase + BLNAR+ 25 (1.4) 21 (1.1)
ß-lactamase- BLNAR+ 105 (6.2) 138 (7.1)
ß-lactamase- BLNAR- 1292 (76.6) 1570 (81.0)
No carriage 693 (19.8) 773 (20.9)
Hi or Pnc carriage 1898 (54.3) 1913 (51.7) 0.09
Hi and Pnc carriage 907 (25.9) 1016 (27.4)
Pnc: pneumococcus; Hi: H. influenzae; BLNAR:
ß-lactamase–nonproducing ampicillin-resistant
Fig. 1 Antibiotic resistance of Streptococcus pneumoniae and Haemophilus influenzae isolated from nasopharyngeal flora in 7200 infants with acute
otitis media between 2006 and 2013. Pnc: pneumococcus; Hi: H. influenzae; BL+: ß-lactamase–producing strains; BLNAR: ß-lactamase–nonproducing
ampicillin-resistant strains
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Table 3 Risk factors of nasopharyngeal carriage of Pnc, strains with reduced susceptibility to penicillin (RSP) Pnc, Hi and ß-lactamase
+ Hi strains by univariate and multivariate analysis
Univariate analysis Multivariate analysis
OR 95 % CI P value aOR 95 % CI P value
Carriage of Pnc*
Otalgia + fever ≥38.5 °C 1.39 1.26;1.53 <10−4 1.29 1.17;1.42 <10−4
Daycare centre 1.33 1.21;1.46 <10−4 1.61 1.46;1.78 <10−4
Siblings 1.32 1.20;1.45 <10−4 1.45 1.31;1.60 <10−4
Age <1 year 1.03 0.94 ;1.14 0.48 1.04 0.95 ;1.15 0.39
Recent use of cephalosporin 0.98 0.86;1.11 0.74
Bilateral AOMa 0.94 0.84;1.06 0.33
Otitis-prone childrenb 0.91 0.79;1.04 0.16
Periods (post-PCV13) 0.86 0.78;0.94 0.002 0.84 0.77 ;0.93 0.01
History of AOMb 0.86 0.77;0.96 0.005
Hi carriage 0.79 0.72 ;0.86 <10−4
Recent use of antibiotics 0.78 0.71 ;0.86 <10−4 0.73 0.66 ;0.81 <10−4
Conjunctivitis 0.47 0.42;0.52 <10−4 0.47 0.42;0.52 <10−4
Carriage of RSP Pnc**
Recent use of antibiotics 1.88 1.66 ;2.14 <10−4 1.78 1.56 ;2.03 <10−4
Day care centre 1.68 1.48;1.91 <10−4 1.55 1.36 ;1.77 <10−4
Recent use of cephalosporin 1.63 1.38;1.92 <10−4
Otitis-prone childrenb 1.60 1.33;1.93 <10−4
History of AOMb 1.58 1.36;1.83 <10−4
Bilateral AOMa 1.15 0.98;1.35 0.08
Age <1 year 1.08 0.96 ;1.23 0.21 1.19 1.04 ;1.35 0.009
Conjunctivitis 1.08 0.93;1.26 0.33
Hi carriage 0.95 0.84 ;1.08 0.46
Otalgia + fever ≥38.5 °C 0.93 0.82;1.06 0.27
Periods (post-PCV13) 0.72 0.63 ;0.81 <10−4 0.71 0.62 ;0.81 <10−4
Siblings 0.70 0.62 ;0.80 <10−4 0.75 0.65 ;0.85 <10−4
Carriage of Hi***
Conjunctivitis 4.22 3.76 ;4.74 <10−4 4.10 3.54 ;4.76 <10−4
Daycare centre 1.74 1.58 ;1.91 <10−4 1.93 1.70;2.19 <10−4
History of AOMb 1.65 1.48 ;1.83 <10−4
Otitis-prone childrenb 1.54 1.34 ;1.77 <10−4
Siblings 1.49 1.36 ;1.64 <10−4 1.82 1.60;2.07 <10−4
Bilateral AOMa 1.47 1.31 ;1.65 <10−4 1.33 1.17 ;1.51 <10−4
Recent use of antibiotics 1.42 1.29;1.56 <10−4 1.28 1.12;1.45 <10−4
Age <1 year 1.37 1.25 ;1.50 <10−4 1.49 1.31;1.69 <10−4
Recent use of cephalosporin 1.19 1.05 ;1.35 0.005
Periods (post-PCV13) 1.18 1.08;1.29 <10−3 1.23 1.05;1.44 0.01
Otalgia + fever ≥38.5 °C 0.84 0.76;0.92 <10−3
Pnc carriage 0.79 0.72 ;0.86 <10−4
Carriage of ß-lactamase producing Hi****
Otitis-prone childrenb 1.27 0.99 ;1.64 0.06
Recent use of cephalosporin 1.21 0.96 ;1.53 0.11
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promoting a judicious use of antibiotics in France, anti-
biotic use in children has been sharply reduced, par-
ticularly for children < 2 years [24]. Furthermore, PCV
implementation may have led to an additional reduc-
tion in prescriptions [25]. The second hypothesis is
more speculative: in our population, most Hi strains
now produce biofilms [26], which allows for resistance
to antibiotic treatments without another mechanism of
resistance required [27, 28].
PCV13 impact in our population was expected since
we have already showed the impact of PCV7 on carriage
and antibiotic resistance [11]. We have previously
showed in pre PCV13 period that Pnc carriage was less
frequently associated with AOM treatment failure than
Hi [29]. However, in this current study, we have not ana-
lyzed the evolution of risk of AOM antibiotic failure be-
tween pre and post PCV13 periods.
This situation of infection and antibiotic resistance is
very dynamic and the few non-vaccine strains of S. pneu-
moniae, which are resistant to penicillin, may, similar to
serotype 19A, become more prevalent. This possibility
underscores the importance of the continuous availabil-
ity of current data that reflects local and national micro-
biologic trends.
Conclusion
The NP carriage rate of RSP-Pnc strains and ß-lactamase–
producing Hi strains has decreased in children with AOM
in France since 2010, the year of PCV13 implementation
in France. Accordingly, amoxicillin as the first-line drug
for AOM requiring antibiotics remains a valid recommen-
dation. However, the AOM microbiology is evolving and
requires continuous monitoring and adjustments of policy
for antibiotics.
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Table 3 Risk factors of nasopharyngeal carriage of Pnc, strains with reduced susceptibility to penicillin (RSP) Pnc, Hi and ß-lactamase
+ Hi strains by univariate and multivariate analysis (Continued)
History of AOMb 1.18 0.94;1.48 0.16
Recent use of antibiotics 1.17 0.97 ;1.40 0.11
Age <1 year 1.16 0.96;1.40 0.12 0.86 0.72;1.04 0.13
Conjunctivitis 1.10 0.91 ;1.33 0.32
Bilateral AOMa 0.96 0.76 ;1.23 0.76
Otalgia + fever ≥38.5 °C 0.94 0.78;1.14 0.52
Siblings 0.91 0.75 ;1.10 0.33
Daycare centre 0.90 0.75;1.08 0.27
Pnc carriage 0.89 0.74 ;1.08 0.24
Periods (post-PCV13) 0.65 0.54 ;0.78 <10−4 0.65 0.54 ;0.79 <10−4
aOR, adjusted odds ratio; 95 % CI, 95 % confidence interval; Pnc: pneumococcus; Hi: H. influenzae; AOM: Acute otitis medi; a adata not available in 2006/2008, bdata
not available in 2006/2007
*univariate and multivariate analysis of overall population (n = 7,200), with 4,033 Pnc carriers; **univariate and multivariate analysis of Pnc carriers (n = 4,033), with
1,735 RSP Pnc carriers; ***univariate and multivariate analysis of overall population (n = 7,200), with 3,624 Hi carriers; ****univariate analysis of Hi carriers (n =
3,624), with 519 ß-lactamase+
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